KKR’s deal is a bet that financing needs from drug companies will continue to rise. - Michael Nagle/Bloomberg News. KKR has ...

Investment firm KKR (KKR) announced on Wednesday the acquisition of a majority stake in the biopharma royalty acquisition company, HealthCare Royalty Partners.

As part of the transaction, HCRx Chairman and CEO Clarke Futch will continue to lead the HCRx team and will maintain an ongoing substantial minority interest in HCRx.

KKR & Co. Inc., a leading global investment firm, today announced that it has acquired a majority ownership stake in HealthCare Royalty Partners (HCRx), a leading biopharma royalty acquisition company ...

Investment giant KKR reported a 9% rise in adjusted net income for the second quarter on Thursday, bolstered by an increase ...

KKR executives said strong momentum in their business gave them confidence on Thursday of beating earnings targets for 2026, ...

Q2 2025 Earnings Call Transcript July 31, 2025 KKR & Co. Inc. beats earnings expectations. Reported EPS is $1.18, ...

KKR continues its aggressive transformation from traditional private equity into a diversified financial powerhouse through strategic acquisitions and fund initiatives. The investment giant recently ...

Q2 2025 Management View Co-CEO Scott C. Nuttall highlighted the company's strong performance, stating that fee-related earnings per share reached $0.98, total operating earnings were $1.33 per share, ...

The firm brought in $1.6 billion from outside investors for its fifth main growth fund and separately promoted dealmaker Sri Rao. The credit-card company reported increases in profit and sales in the ...

Investors are always encouraging startups to push the innovation envelope. General Catalyst's Hemant Taneja is applying that ...